Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report (Q34089078)

30 July 2017

1 reference

title

Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report (English)

1 reference

30 July 2017

cervix uterine cancer

1 reference

Schiller JT

1

1 reference

PubMed ID

11091149

30 July 2017

Hidesheim A

series ordinal

2

1 reference

30 July 2017

1 October 2000

1 reference

Journal of Clinical Virology

30 July 2017

1 reference

30 July 2017

19

1 reference

30 July 2017

1-2

1 reference

30 July 2017

67-74

1 reference

Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Strategies for immunoprophylaxis and immunotherapy of papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Chimeric papillomavirus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Papillomavirus-like particle vaccines for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Advances in vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

HPV6b virus like particles are potent immunogens without adjuvant in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900091-3

7 January 2021

10.1016/S1386-6532(00)00091-3

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11091149